Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Dihua Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6231-9381; OpenAlex author ID A5040450464; NIH RePORTER profile ID 1868182. Sources: OpenAlex.

Their work

Papers
6 (first author 1, last author 1)
Trials
0
Grants
2
Labs led
1
Collaborators
34
Papers, trials and grants by year

2019: 1 grant · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 3 papers · 2025: none · 2026: 1 paper, 1 grant

Papers 6

  1. All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-026-72271-5↗
  2. Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer. Last author DOI 10.1038/s41421-024-00720-w↗
  3. All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer Co-author DOI 10.1101/2024.10.20.619300↗
  4. Regional intra-arterial vs. systemic chemotherapy for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis. First author DOI 10.3389/fonc.2024.1197424↗
  5. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Co-author DOI 10.1126/sciadv.add6995↗
  6. Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma ce… Co-author PMID 33520371↗

Grants 2

  1. Stem Cell Biology & Cellular Therapy Program P30CA016672↗
  2. Co-targeting PDAC tumor cells and the microenvironment to succeed in EGFR/ErbB2-targeted therapy R21CA223102↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mien‐Chie Hung · 5 shared papers, 1 shared grant, 2021–2026 · strength 1.49
  2. Elizabeth J. Shpall · 1 shared grant, 2026 · strength 0.71
  3. Albert C. Koong · 1 shared grant, 2026 · strength 0.71
  4. Kristy Brock · 1 shared grant, 2026 · strength 0.71
  5. Scott Kopetz · 1 shared grant, 2026 · strength 0.71
  6. Haoqiang Ying · 4 shared papers, 2023–2026 · strength 0.63
  7. Paul J. Chiao · 4 shared papers, 2023–2026 · strength 0.63
  8. Yongkun Wei · 3 shared papers, 2024–2026 · strength 0.51
  9. Anirban Maitra · 3 shared papers, 2024–2026 · strength 0.51
  10. Ching-Fei Li · 2 shared papers, 2024–2026 · strength 0.37
  11. Jianhua Ling · 2 shared papers, 2024–2026 · strength 0.37
  12. Ying‐Nai Wang · 2 shared papers, 2024–2026 · strength 0.37
  13. Jie Fu · 2 shared papers, 2024–2026 · strength 0.37
  14. Li‐Yuan Bai · 2 shared papers, 2024–2026 · strength 0.37
  15. Huamin Wang · 2 shared papers, 2024–2026 · strength 0.35
  16. Wei Zhu · 1 shared paper, 2024 · strength 0.31
  17. Yanjie Cao · 1 shared paper, 2024 · strength 0.31
  18. Liuqing Yang · 2 shared papers, 2021–2023 · strength 0.27
  19. Jun Yao · 2 shared papers, 2023–2024 · strength 0.27
  20. Cheng‐Wei Chou · 1 shared paper, 2026 · strength 0.21
  21. Wantong Yao · 1 shared paper, 2026 · strength 0.21
  22. Yingbin Liu · 1 shared paper, 2021 · strength 0.15
  23. Yuan Gao · 1 shared paper, 2021 · strength 0.15
  24. Rosa F. Hwang · 1 shared paper, 2024 · strength 0.14
  25. Yohei Saito · 1 shared paper, 2024 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.